Physician profile
Keith I Lenchner
NPI 1669421491
$10,842.97
in general payments reported to CMS, 2019-2025
37 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $801 · 2021: $1,273 · 2022: $1,480 · 2023: $1,542 · 2024: $1,911 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,403 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,403.01 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,517.14 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Pharming Healthcare, INC. | $965.54 | 2019-2025 | Ruconest |
| Genzyme Corporation | $952.87 | 2020-2025 | |
| Glaxosmithkline, LLC. | $684.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $648.55 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Biocryst US Sales Co., LLC | $575.29 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $570.08 | 2019-2025 | Dupixent |
| Csl Behring | $496.14 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Octapharma USA, INC. | $440.03 | 2020-2024 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $406.42 | 2019-2025 | |
| Genentech USA, INC. | $380.75 | 2020-2025 | Xolair |
| Optinose US, INC. | $260.45 | 2019-2025 | |
| Grifols USA, LLC | $243.96 | 2022-2025 | Xembify |
| Pfizer INC. | $243.05 | 2019-2025 | |
| Kaleo, INC. | $232.18 | 2019-2024 | Auvi-Q |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lenchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.